Jpmorgan Chase & CO Lava Therapeutics Nv Call Options Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
Call Options
0 transactions
Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
---|
Others Institutions Holding LVTX
# of Institutions
21Shares Held
4.84MCall Options Held
17.9KPut Options Held
200-
Redmile Group, LLC San Francisco, CA2.07MShares$3.22 Million0.33% of portfolio
-
Bml Capital Management, LLC Zionsville, IN1.97MShares$3.05 Million1.97% of portfolio
-
Bruce & Co., Inc. Chicago, IL522KShares$808,9040.29% of portfolio
-
Pnc Financial Services Group, Inc. Pittsburgh, PA65KShares$100,7500.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il51.8KShares$80,2960.0% of portfolio
About LAVA Therapeutics NV
- Ticker LVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,797,700
- Market Cap $40M
- Description
- LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer...